Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial - Cortes, J; Cescon, D W; Rugo, H S; KEYNOTE-355 Investigators (Lancet, 2020)
(10265):